Employees: 641
Size Oncology Institute (STLN) is a United States Health Care company (Medical/Nursing Services) with a market value of $326M, the 3007th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.20 on 18 Nov 2026.
Growth Revenue grew 34.6% over the last twelve months (peer median +5.1%); the operating margin is -3.3% (peer median 8.4%).
Valuation It trades at 0.6× enterprise value to sales against a peer median of 1.9× (2nd cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +22%, so the hurdle is -16 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 63.0 points below its cost of capital (7.0% WACC).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $620M | $503M | $393M | $324M | $252M |
| Revenue growth | — | +28% | +21% | +28% | — |
| Gross profit | $97.3M | $69.5M | $47.7M | $53.7M | $47.7M |
| EBITDA | -$13.6M | -$29.1M | -$53.8M | -$54.2M | -$66.8M |
| Net income | -$30.1M | -$50.3M | -$53.0M | -$67.9M | $132,000 |
| Free cash flow | $18.8M | -$27.8M | -$30.3M | -$40.9M | -$67.3M |
| Capital expenditure | $4.27M | $3.20M | $3.79M | $4.57M | $5.53M |
| Total debt | $103M | $104M | $123M | $120M | $108M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | STLN | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -51.7% | -6.8% | lowest of 21 |
| Distance from 52-week high | -55.1% | -26.3% | 3rd lowest of 21 |
| Revenue growth (TTM) | +34.6% | +5.1% | 3rd highest of 21 |
| Operating margin | -3.3% | 8.4% | 5th lowest of 21 |
| EV / Sales | 0.6× | 1.9× | 2nd cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 5.4% | 6.6% | 8th least demanding of 17 |
| Growth delivered (Del g) | +21.8% | +15.4% | 6th highest of 17 |
| Hurdle (Req g minus delivered) | -16.4 pp | -10.9 pp | 7th least demanding of 17 |
| ROIC minus cost of capital | -63.0 pp | -0.3 pp | lowest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Oncology Institute STLN | United States | $326M | n/a | +35% | -3% | 0.6× | 5.4% | +21.8% |
| NIOX NIOX.L | United Kingdom | $325M | +3% | +3% | 22% | 4.9× | 3.4% | +15.3% |
| Tellgen 300642.SZ | China | $328M | -11% | +5% | 8% | 5.2× | 18.8% | -5.8% |
| Auna AUNA | United States | $309M | -5% | +17% | 13% | 1.0× | -10.7% | +24.4% |
| Universal Vision Biotechnology 3218.TWO | Taiwan | $309M | -4% | +5% | 31% | 2.4× | -13.8% | +15.4% |
| Australian Unity Ltd Pref AYUPA.AX | Australia | $352M | +17% | 0% | -2% | 0.4× | -14.9% | +9.6% |
| Dr. Agarwal'S Eye Hospital DRAGARWQ.NS | India | $292M | +14% | +20% | 21% | 5.5× | 19.6% | +27.5% |
| M1 Kliniken M12.DE | Germany | $368M | +1% | -28% | 13% | 1.2× | -5.3% | +17.9% |
| ADICON 9860.HK | Hong Kong | $393M | +5% | +1% | 4% | 1.3× | 12.3% | -1.5% |
| Jeena Sikho Lifecare JSLL.NS | India | $394M | -55% | +135% | 32% | 4.0× | 7.3% | +42.6% |
| Integral Diagnostics IDX.AX | Australia | $413M | -22% | +26% | 9% | 1.5× | 7.8% | +17.7% |
| Australian Clinical Labs ACL.AX | Australia | $418M | +68% | -1% | 8% | 1.3× | 4.3% | +2.6% |
| Strata Critical Medical SRTA | United States | $443M | -10% | +23% | -4% | 1.4× | n/a | n/a |
| JS Link 127120.KS | South Korea | $458M | -62% | +39% | -83% | 25.2× | n/a | n/a |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $518M | -17% | -19% | 6% | 2.3× | 5.9% | +3.2% |
| Ginkgo Bioworks DNA | United States | $547M | +9% | -44% | -242% | 6.5× | n/a | n/a |
| WELL Health Technologies WELL.TO | Canada | $661M | -9% | +29% | 6% | 1.2× | 10.1% | +94.5% |
| Fulgent Genetics FLGT | United States | $702M | +53% | +5% | -38% | 1.2× | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $702M | +1% | +33% | 13% | 5.6× | 36.6% | +31.6% |
| GMR Solutions GMRS | United States | $714M | -8% | -4% | 14% | 0.9× | -19.6% | -4.0% |
| Jinxin Fertility 1951.HK | Hong Kong | $758M | -4% | +7% | 11% | 2.8× | 17.8% | +12.4% |